PLSE Insider Trading Activity and SEC Form 4 Filings
PLSE insider trading summary
Over the past 12 months, insiders at Pulse Biosciences, Inc. (PLSE) reported 8 open-market purchases worth $26.8M by 3 insiders and 6 sales worth $2.8M by 1 insider on SEC Form 4. Net insider buying was $24.0M.
Latest PLSE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Liane Rae Teplitsky | Chief Operating Officer | Buy | $50K (1,001 @ $49.95) |
| Aug 31, 2026 | Liane Rae Teplitsky | Chief Operating Officer | Buy | $50K (1,024 @ $48.80) |
| Aug 28, 2026 | Liane Rae Teplitsky | Chief Operating Officer | Buy | $50K (1,034 @ $48.35) |
| Aug 26, 2026 | Liane Rae Teplitsky | Chief Operating Officer | Buy | $50K (1,036 @ $48.23) |
| May 11, 2026 | Robert W Duggan | Director | Buy | $13.0M (660,233 @ $19.69) |
| May 11, 2026 | Paul A Laviolette | Chief Executive Officer | Buy | $295K (15,000 @ $19.69) |
| May 11, 2026 | Robert W Duggan | Director | Buy | $13.0M (660,233 @ $19.69) |
| May 11, 2026 | Paul A Laviolette | Chief Executive Officer | Buy | $295K (15,000 @ $19.69) |
| Feb 17, 2026 | Kevin Patrick Danahy | Chief Commercial Officer | Sell | $473K (20,000 @ $23.63) |
| Feb 13, 2026 | Kevin Patrick Danahy | Chief Commercial Officer | Sell | $471K (20,000 @ $23.53) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.